Evidence map›Paper›PMID 36452496›Full record

ArticleFrontiers in oncology2022

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma.

Yuanyuan Gu, Jing Meng, Yongzhi Ju, Xia You, Tingting Sun, Jun Lu, Yin Guan

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yuanyuan GuDepartment of Medical Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Jing MengDepartment of Medical Oncology, The Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Yongzhi JuThe Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Xia YouThe Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Tingting SunThe Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Jun LuDepartment of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yin GuanDepartment of Medical Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Simcere Pharmaceutical (China) · CNCapital Medical University · CNBeijing Chao-Yang Hospital · CNChinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiosarcoma (AS) is a rare, clinically aggressive tumor with limited treatment options and a poor prognosis. Mutations involving the angiogenesis-related genes

Indexed as

anlotinibcutaneous angiosarcomasFLT4soft tissue sarcomasvascular endothelial growth factor receptor (VEGFR)

Identifiers

PMID36452496
PMCPMC9702819
OpenAlexW4309039906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.